{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"26"}]}],"title":"mSWAT skin response (CR/PR)flare considered as disease progression ( f.i.p ) - Number of responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"33"}]}],"title":"Physician's Global Assessment- Responder (CR/PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"139"}],"units":"Participants"}],"description":"Estimate of the response rate of participants with resistant cutaneous T-cell lymphoma (CTCL) treated with Panobinostat using the mSWAT skin scores and 95% CI will be analyzed.","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed.Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"Bexarotene Exposed"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG001","title":"Bexarotene Naive"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG002","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis was performed in FAS population was defined according to the intention-to-treat principle. This population will include all participants enrolled into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 12, an average of 12 months","title":"The Overall Response Rate Using mSWAT Skin Score","type":"SECONDARY","unitOfMeasure":"Participants"}